66,375 results match your criteria Neutropenia


Three patients with glucose-6 phosphatase catalytic subunit 3 deficiency.

J Pediatr Endocrinol Metab 2020 Jul 5. Epub 2020 Jul 5.

Department of Pediatrics, Division of Pediatric Immunology, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Objectives Severe congenital neutropenia (SCN) is a primary immunodeficiency (PID) characterized by persistent severe neutropenia, recurrent infections, and oral aphthous lesions. Severe congenital neutropenia is caused by various genetic defects such as ELANE, GFI, HAX-1, JAGN1, SRP54, and glucose-6 phosphatase catalytic subunit 3 (G6PC3) deficiency. Clinical features of the patients with G6PC3 deficiency vary from neutropenia to several systemic features in addition to developmental delay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/jpem-2019-0541DOI Listing

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).

Eur J Cancer 2020 Jul 2;136:25-34. Epub 2020 Jul 2.

Department of Hepato-gastroenterology, Sorbonne Paris City, Paris Descartes University, Georges Pompidou European Hospital, Paris, France. Electronic address:

Background: Chemotherapy is effective in metastatic pancreatic adenocarcinoma (mPA), but new approaches are still needed to improve patients' survival and quality of life. We have previously published good efficacy and tolerability results on a sequential treatment strategy of gemcitabine followed by an intensified FOLFIRI (5FU+irinotecan) regimen. In the present study, we evaluated the same sequence but replaced gemcitabine by the new gemcitabine + nab-paclitaxel standard first-line combination. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2020.05.018DOI Listing

The impact of emergency department triage on the treatment outcomes of cancer patients with febrile neutropenia: A retrospective review.

Int Emerg Nurs 2020 Jul 1;51:100888. Epub 2020 Jul 1.

MUN School of Medicine, St. John's, Canada. Electronic address:

Introduction: The emergency department (ED) is an important entry point for patients with cancer requiring acute care due to oncological emergencies. Febrile neutropenia (FN) is one of the most common oncological emergencies and carries a significant risk of morbidity and mortality. There is evidence from previous studies that FN patients wait far longer in the ED than recommended by international guidelines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ienj.2020.100888DOI Listing

Is PEGylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and meta-analysis.

Support Care Cancer 2020 Jul 3. Epub 2020 Jul 3.

Department of Breast Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430079, Hubei, People's Republic of China.

Background: PEGylated granulocyte colony-stimulating factor (G-CSF) is a safe alternative to G-CSF to improve chemotherapy-induced neutropenia (CIN). This superiority has resulted in its increased use by physicians; however, the superiority of PEGylated G-CSF for CIN in breast cancer has not been conclusively determined.

Objectives: To assess the superiority of PEGylated G-CSF for CIN in breast cancer in terms of effectiveness and safety via a systematic review and meta-analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-020-05603-wDOI Listing

Poikiloderma with Neutropenia, Clericuzio-Type Accompanied by Loss of Digits Due to Severe Osteomyelitis.

J Clin Immunol 2020 Jul 4. Epub 2020 Jul 4.

School of Medicine, Department of Dermatology and Venereology, Hacettepe University, Ankara, Turkey.

Poikiloderma with neutropenia (PN), Clericuzio-type is a rare autosomal recessively transmitted genodermatosis caused by biallelic mutations in the USB1 gene and is characterized by early-onset poikiloderma and chronic neutropenia. Nail dystrophy, palmoplantar hyperkeratosis, hypogonadotropic hypogonadism, and recurrent infections can be associated with the disease. Herein, we present a 27-year-old Turkish male patient newly diagnosed as PN, Clericuzio-type after confirmation of a c. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10875-020-00815-5DOI Listing

A novel silkworm infection model with fluorescence imaging using transgenic Trichosporon asahii expressing eGFP.

Sci Rep 2020 Jul 3;10(1):10991. Epub 2020 Jul 3.

Department of Microbiology, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose, Tokyo, 204-8588, Japan.

Trichosporon asahii is a pathogenic fungus that causes deep mycosis in patients with neutropenia. Establishing an experimental animal model for quantitatively evaluating pathogenicity and developing a genetic recombination technology will help to elucidate the infection mechanism of T. asahii and promote the development of antifungal drugs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-67841-6DOI Listing

Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer.

Cancer Sci 2020 Jul 3. Epub 2020 Jul 3.

National Hospital Organization, Osaka National Hospital, Osaka, Japan.

The ongoing, Phase Ib MONALEESASIA study is evaluating the efficacy and safety of ribociclib plus endocrine therapy in Asian patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Eligible patients from Japan, Hong Kong, and Singapore were enrolled in this 2-phase study consisting of a dose-escalation phase to determine the maximum-tolerated dose and the recommended Phase II dose of ribociclib plus letrozole, and a dose-expansion phase to evaluate safety and tolerability of ribociclib plus letrozole, fulvestrant, or tamoxifen. An exploratory biomarker analysis evaluating expression of target genes was also conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.14554DOI Listing

Acute Appendicitis in a Child With Acute Leukemia and Chemotherapy-Induced Neutropenia: A Case Report and Literature Review.

Cureus 2020 Jun 27;12(6):e8858. Epub 2020 Jun 27.

Nephrology, Salmaniya Medical Complex, Manama, BHR.

Acute appendicitis is a rare but important complication in children with leukemia. It can be difficult to diagnose, and it has a complicated disease course, especially in patients receiving chemotherapy. Awareness of these complications is critical, particularly in cases where surgical intervention is required. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.8858DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325351PMC

Systemic lupus erythematosus and neutropaenia: a hallmark of haematological manifestations.

Lupus Sci Med 2020 Jul;7(1)

Department of Clinical Immunology and Internal Medicine, National Reference Center for autoimmune diseases (RESO), Strasbourg University Hospital, Strasbourg, France.

Objective: Systemic lupus is a chronic autoimmune disease characterised by its phenotypic heterogeneity. Neutropaenia is a frequent event in SLE occurring in 20%-40% of patients depending on the threshold value of neutrophil count. On a daily basis, the management of neutropaenia in SLE is difficult with several possible causes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/lupus-2020-000399DOI Listing

Phase I study of duvelisib in Japanese patients with relapsed or refractory lymphoma.

Int J Hematol 2020 Jul 1. Epub 2020 Jul 1.

Department of Medicine and Biosystemic Science, Faculty of Medicine, Kyusyu University, Fukuoka, Japan.

Duvelisib is a novel dual inhibitor of phosphoinositide-3-kinase (PI3K)-δ and -γ. This single-arm, multicenter phase I study investigated its safety, pharmacokinetics, and preliminary efficacy in Japanese patients with relapsed or refractory lymphoma. Duvelisib was administered orally twice daily at 25 mg in 28-day cycles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-020-02929-3DOI Listing

Intestinal Perforation due to Neutropenic Enterocolitis in a Patient Treated with Bevacizumab for Ovarian Cancer.

Case Rep Oncol Med 2020 16;2020:7231358. Epub 2020 Jun 16.

Department of Breast and Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

Intestinal perforation is a rare adverse event of antineoplastic therapy. However, once it occurs, it is potentially fatal. This report describes a case of intestinal perforation caused by bevacizumab in a patient with ovarian cancer who concurrently developed neutropenic enterocolitis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/7231358DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317333PMC

Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents.

Ther Adv Psychopharmacol 2020 22;10:2045125320935306. Epub 2020 Jun 22.

South London and Maudsley NHS Foundation Trust, London, UK.

As yet, no agents have been approved for the treatment of COVID-19, although several experimental drugs are being used off licence. These may have serious adverse effects and potential drug interactions with psychotropic agents. We reviewed the common agents being used across the world for the treatment of COVID-19 and investigated their drug interaction potential with psychotropic agents using several drug interaction databases and resources. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2045125320935306DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309390PMC

Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days.

Bone Marrow Transplant 2020 Jul 1. Epub 2020 Jul 1.

Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

We compared three fludarabine-based regimens for systemic sclerosis patients with a high-risk cardiac phenotype that according to EBMT criteria would be a contraindication for a high-dose cyclophosphamide (200 mg/kg) transplant regimen. All three regimens included fludarabine, ATG, and cyclophosphamide (60 mg/kg), while two regimens also included rituximab with or without IVIG. Treatment related mortality (TRM) was 2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0978-2DOI Listing

Homozygote CRIM1 variant is associated with thiopurine-induced neutropenia in leukemic patients with both wildtype NUDT15 and TPMT.

J Transl Med 2020 Jul 1;18(1):265. Epub 2020 Jul 1.

Division of Biomedical Informatics, Seoul National University Biomedical Informatics (SNUBI), Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea.

Background: NUDT15 and TPMT variants are strong genetic determinants of thiopurine-induced hematological toxicity that results in therapeutic failure in pediatric acute lymphoblastic leukemia (ALL). However, many patients with both wild-type (WT) NUDT15 and TPMT still suffer from thiopurine toxicity and therapeutic failure.

Methods: Whole-exome sequencing was done for discovery (N = 244) and replication (N = 76) cohorts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-020-02416-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328279PMC

Periodic hematological disorders: Quintessential examples of dynamical diseases.

Authors:
Michael C Mackey

Chaos 2020 Jun;30(6):063123

Department of Physiology, Department of Physics, and Department of Mathematics McGill University, Montreal, Quebec H4X 2C1, Canada.

This paper summarizes the evidence supporting the classification of cyclic neutropenia as a dynamical disease and periodic chronic myelogenous leukemia is also considered. The unsatisfactory state of knowledge concerning the genesis of cyclic thrombocytopenia and periodic autoimmune hemolytic anemia is detailed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1063/5.0006517DOI Listing

Pimasertib Versus Dacarbazine in Patients With Unresectable -Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover.

Cancers (Basel) 2020 Jun 29;12(7). Epub 2020 Jun 29.

Department of Dermato Cancerology, CIC 1413, CRCINA Inserm 1232, CHU Nantes, 44093 Nantes, France.

This study investigated the efficacy and safety of pimasertib (1/2 inhibitor) versus dacarbazine (DTIC) in patients with untreated -mutated melanoma. Phase II, multicenter, open-label trial. Patients with unresectable, stage IIIc/IVM1 -mutated cutaneous melanoma were randomized 2:1 to pimasertib (60 mg; oral twice-daily) or DTIC (1000 mg/m; intravenously) on Day 1 of each 21-day cycle. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12071727DOI Listing

Early Supported Discharge for patients with febrile neutropenia - Experience at a large district hospital in the UK.

Acute Med 2019 ;18(1):14-19

PhD; Taunton and Somerset NHS Foundation Trust.

Neutropenic sepsis can be life threatening, with mortality 2-21%. The heterogeneity of patients referred with "suspected neutropenic sepsis" has led to strategies being developed to risk-stratify patients and identify those with a low risk of septic complications that could be managed in the outpatient setting, such as The Multinational Association for Supportive Care in Cancer score (MASCC). Outcomes for patients referred with suspected neutropenic sepsis were assessed before and after use of MASCC guided early-supported discharge. Read More

View Article

Download full-text PDF

Source
January 2019

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma.

Cancer Med 2020 Jul 1. Epub 2020 Jul 1.

Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.

Background: Even in the era of novel immunotherapies for multiple myeloma (MM), treatment of late-stage relapsed/refractory (RR) patients remains challenging. The aim of our study was to analyze the efficacy and safety of the five-drug combination pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in RRMM.

Methods: We retrospectively analyzed data of 56 patients with RRMM who received Pom-PAD-Dara between September 2016 and May 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3209DOI Listing

Association of New Coronavirus Disease with Fragility Hip and Lower Limb Fractures in Elderly Patients.

Arch Bone Jt Surg 2020 Apr;8(Suppl1):297-301

Orthopedic Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

The novel coronavirus-induced infection (COVID-19) was declared a pandemic by the World Health Organization on March 11, 2020. Iran is one of the countries with a high incidence of COVID-19 infection. Data on three patients with fragility hip fracture and COVID-19 infection were collected from one hospital located in Badrud, Isfahan, Iran, from March 1, 2010, to March 30, 2020. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.22038/abjs.2020.47626.2333DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296606PMC

Coexistence of diverse heavy metal pollution magnitudes: Health risk assessment of affected cattle and human population in some rural regions, Qena, Egypt.

J Adv Vet Anim Res 2020 Jun 10;7(2):345-359. Epub 2020 May 10.

Department of Biology, Faculty of Science, King Khalid University, Abha, Saudi Arabia.

Objective: The purpose of this study was to measure the mean concentrations of heavy metals including aluminum (Al), arsenic, nickel (Ni), mercury, lead (Pb), and cadmium (Cd) and to assess the health hazards due to the exposure of cattle/human population to a distinct or the mixture of heavy metals through various sources.

Materials And Methods: A total of 180 samples including water sources, animal feed, and raw cows' milk from rural regions in Qena, Egypt, were examined using the inductively coupled plasma emission spectrometer (ICP; iCAP 6200).

Results: The data highlighted heavy metal pollution with variable concentrations among most of the investigated regions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5455/javar.2020.g428DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320808PMC

Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer.

Cancer Manag Res 2020 23;12:4911-4921. Epub 2020 Jun 23.

Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara-City, Kanagawa 252-0374, Japan.

Purpose: Amrubicin (AMR) is an anticancer drug for patients with relapsed small-cell lung cancer (SCLC). However, the efficacy of AMR in elderly patients with relapsed SCLC after chemotherapy by carboplatin plus etoposide (CE) has not been sufficiently evaluated.

Patients And Methods: The medical records of patients with relapsed SCLC who received AMR as second-line chemotherapy were retrospectively reviewed, and their treatment outcomes were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S255552DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320750PMC

A Systematic Review of Vancomycin Dosing in Patients with Hematologic Malignancies or Neutropenia.

Infect Drug Resist 2020 16;13:1807-1821. Epub 2020 Jun 16.

Department of Pharmacy, Peking University Third Hospital, Beijing, People's Republic of China.

Objective: To provide a comprehensive review of vancomycin dosing in patients with hematologic malignancies or neutropenia.

Methods: PubMed, Embase and the Cochrane Library were searched through April 2, 2020. Original studies relevant to vancomycin dosing regimen in adults with hematologic malignancies or neutropenia were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/IDR.S239095DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305817PMC

A Comparison of the BEAM and MITO/MEL Conditioning Regimens for Autologous Hematopoietic Stem Cell Transplantation in Hodgkin Lymphoma: An Analysis of Efficiency and Treatment-Related Toxicity.

Clin Lymphoma Myeloma Leuk 2020 May 21. Epub 2020 May 21.

Baskent University Adana Adult Bone Marrow Transplantation Center, Adana, Turkey.

Background: Approximately half of patients with relapsed chemosensitive disease achieve robust responses with BEAM (BCNU, etoposide, cytarabine, and melphalan) and autologous stem cell rescue. The scarcity of comparative studies further limits alternative treatment protocols, such as the MITO/MEL (mitoxantrone, melphalan) protocol.

Patients And Methods: In this retrospective multicenter study, we compared the BEAM and MITO/MEL regimens used before autologous hematopoietic stem cell transplantation (ASCT) in terms of efficacy and side effects in patients with Hodgkin lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.05.009DOI Listing

A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide.

Clin Lymphoma Myeloma Leuk 2020 May 13. Epub 2020 May 13.

Department of Internal Medicine III, Charité Campus Benjamin Franklin, Berlin, Germany.

Introduction: Lenalidomide plus dexamethasone is effective and well tolerated in relapsed/refractory multiple myeloma (RRMM). In this observational, noninterventional European post-authorization safety study, the safety profile of lenalidomide plus dexamethasone was investigated and compared with that of other agents in the treatment of RRMM in a real-world setting.

Patients And Methods: Patients had received ≥ 1 prior antimyeloma therapy; prior lenalidomide was excluded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.05.006DOI Listing

A novel VPS13B mutation in Cohen syndrome: a case report and review of literature.

BMC Med Genet 2020 Jun 30;21(1):140. Epub 2020 Jun 30.

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.

Background: Cohen syndrome, an autosomal recessive syndrome, is a rare syndrome with diverse clinical manifestations including failure to thrive, hypotonia, hypermobile joints, microcephaly, intellectual disabilities, craniofacial and limb anomalies, neutropenia and a friendly character. It is associated with mutations of the vacuolar protein sorting 13 homolog B (VPS13B) gene, which is involved in the development of the ocular, hematological and central nervous systems. This gene encodes a transmembrane protein playing a crucial role in preserving the integrity of the Golgi complex. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12881-020-01075-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325105PMC

Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.

Am J Clin Oncol 2020 Jun 26. Epub 2020 Jun 26.

Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam.

Objective: By using the Korean Pancreatic Cancer (K-PaC) registry, we compared the clinical outcomes of FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GNP) in patients with metastatic pancreatic cancer (MPC).

Methods: We constructed a web-based database of 3748 anonymized patients diagnosed with pancreatic ductal adenocarcinoma. MPC patients who received first-line FFX or GNP were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000730DOI Listing

Peptide Receptor Radionuclide Therapy as First-Line Systemic Treatment in Advanced Inoperable/Metastatic Neuroendocrine Tumors.

Clin Nucl Med 2020 Jun 25. Epub 2020 Jun 25.

General Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Purpose: Advanced inoperable/metastatic neuroendocrine tumors (NETs) pose a therapeutic challenge with limited treatment options. Peptide receptor radionuclide therapy (PRRT), being specific in targeting the somatostatin receptors, is a promising and viable option in this setting. In this study, we intended to evaluate the role of PRRT as the first-line systemic therapy in advanced inoperable/metastatic NETs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000003170DOI Listing

Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (Lu-J591) for metastatic castration-resistant prostate cancer.

Urol Oncol 2020 Jun 26. Epub 2020 Jun 26.

Department of Urology, Weill Cornell Medicine, New York, NY; Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY; Meyer Cancer Center, Weill Cornell Medicine, NewYork Presbyterian Hospital, New York, NY. Electronic address:

Background: Docetaxel remains a standard of care for metatsatic castration resistant porstate cancer (mCRPC) and has radiosensitizing properties. The dose limiting toxicity (DLT) of radioimmunotherapy is myelosuppression; dose fractionation of Lu-J591 allows similar administered doses with less toxicity. This study (NCT00916123) was designed to determine the safety, DLT, and maximum tolerated dose of fractionated Lu-J591 administered concurrently with standard docetaxel. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2020.05.028DOI Listing

Patients Undergoing Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation Exhibit Depleted Vitamin C Status in Association with Febrile Neutropenia.

Nutrients 2020 Jun 24;12(6). Epub 2020 Jun 24.

The Infection Group, Department of Pathology and Biomedical Science, University of Otago, Christchurch 8011, New Zealand.

Patients undergoing myeloablative chemotherapy and hematopoietic stem cell transplantation (HSCT) experience profound neutropenia and vulnerability to infection. Previous research has indicated that patients with infections have depleted vitamin C status. In this study, we recruited 38 patients with hematopoietic cancer who were undergoing conditioning chemotherapy and HSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/nu12061879DOI Listing

[Fatal severe community-acquired pneumonia: risk factors, clinical characteristics and medical errors of hospital patients].

Ter Arkh 2020 Apr 27;92(3):42-49. Epub 2020 Apr 27.

Kazan (Volga Region) Federal University.

Community-acquired pneumonia (CAP) is the most common disease and potentially life-threatening infection in the worldwide. In the Nizhny Novgorod region, no analysis of the causes of mortality and medical errors of severe CAP patients.

Aim: To analyze the patients structure who died severe CAP in hospitals of the Nizhny Novgorod region, to identify the leading risk factors, to assess the clinical characteristics of fatal severe CAP and medical errors according to medical records of patients from 20152016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/00403660.2020.03.000538DOI Listing

[Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma].

Ter Arkh 2019 Jul 15;91(7):41-51. Epub 2019 Jul 15.

National Research Center for Hematology.

Mantle cell lymphoma (MCL) is aggressive B-cell neoplasm diagnosed predominantly among older men. R-CHOP-like regimens allow to achieve high response rate, but the overall survival (OS) are disappointingly short - 3-4 years. An addition of high - dose cytarabine to the upfront therapy and autoSCT significantly improved outcomes but remain feasible largely for medically fit patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/00403660.2019.07.000322DOI Listing

Therapeutic effect and side effects of Bevacizumab combined with Irinotecan in the treatment of paediatric intracranial tumours: Meta-analysis and Systematic Review.

J Clin Pharm Ther 2020 Jun 29. Epub 2020 Jun 29.

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

What Is Known And Objective: Bevacizumab (BVZ) is an angiogenesis inhibitor that often works well with chemotherapeutic drugs for the treatment of solid intracranial tumours in children. This meta-analysis discusses the efficacy and side effects of BVZ combined with irinotecan in the treatment of patients (younger than 21 years of age) with recurrent, progressive or refractory intracranial tumours.

Methods: We searched for articles published before 31 October 2018 in PubMed, EMBASE, Cochrane library and Web of Science. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jcpt.13228DOI Listing

Applying the 2019 EULAR/ACR Lupus Criteria to Patients from the LUMINA Cohort.

Arthritis Care Res (Hoboken) 2020 Jun 29. Epub 2020 Jun 29.

Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, US, United States.

Objective: To evaluate the performance of the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) criteria for Systemic Lupus Erythematosus (SLE) in terms of earlier SLE classification in comparison to the ACR or the Systemic Lupus International Collaborating Clinics (SLICC) criteria.

Materials And Methods: Patients from a multiethnic, multicenter cohort, the LUMINA cohort, where SLE was defined using the 1982/1997 ACR criteria were included. Demographic, clinical, and immunologic criteria were compared among the 2019 EULAR/ACR and the 1982/1997 ACR and the 2012 SLICC timing categories. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.24367DOI Listing

Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial).

Gastric Cancer 2020 Jun 28. Epub 2020 Jun 28.

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Background: In East Asia, S-1 plus cisplatin (SP) is one of the standard first-line chemotherapy regimens for metastatic or recurrent gastric cancer (MRGC). Oxaliplatin is generally less toxic and more convenient to administer than cisplatin.

Patients And Methods: This was a multicenter, phase III study assessing whether S-1/oxaliplatin (SOX) was non-inferior/superior to SP in terms of progression-free survival (PFS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10120-020-01101-4DOI Listing

Concurrent use of palbociclib and radiation therapy: single-centre experience and review of the literature.

Br J Cancer 2020 Jun 29. Epub 2020 Jun 29.

Department of Radiation Oncology, Curie Institute, Paris, France.

Palbociclib in combination with endocrine therapy increases progression-free survival in patients with ER-positive, HER2-negative advanced breast cancer (BC). In this study, we retrospectively evaluated safety in the first patient treated with concurrent use of palbociclib and radiation therapy (RT) in the Curie Institute. Between April 2017 and August 2019, 30 women with metastatic BC received locoregional and/or symptomatic irradiation at a metastatic site concurrently with palbociclib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0957-9DOI Listing

Angiotensin II for the treatment of septic shock in a neutropenic patient with T-cell acute lymphoblastic leukaemia.

BMJ Case Rep 2020 Jun 28;13(6). Epub 2020 Jun 28.

Critical Care, Mayo Clinic Florida, Jacksonville, Florida, USA

Mortality remains high in septic shock with few new treatment options. Angiotensin II has been recently approved for use in septic shock due to promising results in the ATHOS-3 trial. However, patients with neutropenia were excluded in the trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2019-233432DOI Listing

Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients.

Hematol Oncol 2020 Jun 28. Epub 2020 Jun 28.

Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.

First line therapy of patients with marginal zone lymphomas (MZL) is not well established and various regimens with chemo-immunotherapy can be used. Rituximab plus bendamustine (BR) is an effective and manageable treatment option for patients affected by indolent non-Hodgkin lymphoma. The aim of this monocentric retrospective study was to analyze the effectiveness and safety of the use of BR regimen in MZL patients in first line in daily clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2773DOI Listing

Dysfunctional Immune System Reconstitution After Rituximab Exposure In Utero.

J Pediatr Hematol Oncol 2020 Jun 23. Epub 2020 Jun 23.

Pediatric Hematology and Oncology, Walter Reed National Military Medical Center.

Rituximab is an antibody that binds to B-lymphocytes and is increasingly used during pregnancy. As an immunoglobulin G, it will transfer across the placenta. Previous case reports describe a diversity of clinical presentations in neonates born following rituximab exposure in utero. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000001871DOI Listing

Procalcitonin Clearance, CD64, and HLA-DR as Predictors of Outcome in Febrile Neutropenic Children With Lymphoreticular Malignancies.

J Pediatr Hematol Oncol 2020 Jun 23. Epub 2020 Jun 23.

Microbiology, University College of Medical Sciences & Guru Teg Bahadur Hospital, Delhi.

Background: Febrile neutropenia (FN) is a dreaded complication of cancer chemotherapy. There has been a lot of improvement in supportive care in FN that has drastically reduced the infection-related mortality in these patients. The focus now is on reducing infection-related morbidity, healthcare costs and optimizing the quality of life of the child as well as their family during these episodes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000001870DOI Listing

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.

Lancet Haematol 2020 Jul;7(7):e511-e522

Hospital Universitario La Paz, Madrid, Spain.

Background: Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer with a median overall survival of less than 6 months. We aimed to assess the response to single-agent selinexor, an oral selective inhibitor of nuclear export, in patients with relapsed or refractory DLBCL who had no therapeutic options of potential clinical benefit.

Methods: SADAL was a multicentre, multinational, open-label, phase 2b study done in 59 sites in 19 countries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(20)30120-4DOI Listing

A single-arm study of systemic and sub-Tenon chemotherapy for Groups C and D intraocular retinoblastoma: A Children's Oncology Group study (ARET 0231).

Pediatr Blood Cancer 2020 Jun 26:e28502. Epub 2020 Jun 26.

The Retinoblastoma Center of Houston, Houston, Texas.

Background: Eyes with Group D intraocular retinoblastoma have low salvage rates. A pilot study showed safety and efficacy of sub-Tenon's fascia carboplatin with systemic chemotherapy supporting further study.

Methods: Children with newly diagnosed bilateral intraocular retinoblastoma with at least one remaining Group C or D eye were treated with six courses of carboplatin/etoposide/vincristine (CEV) with sub-Tenon's fascia carboplatin for Group C/D eyes during courses 2-4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.28502DOI Listing

Platinum-based chemotherapy in advanced triple-negative breast cancer: a multicenter real-world study in China.

Int J Cancer 2020 Jun 25. Epub 2020 Jun 25.

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Platinum-based chemotherapy(PBC) has proven benefits in phase III studies for advanced triple-negative breast cancer(TNBC) patients; however, real-world data of large samples from multiple centers are lacking. This study was to compare the effectiveness of PBC and non-PBC in advanced TNBC patients in multicenter real-world settings. Totally, 495 patients with advanced TNBC receiving PBC(n = 350) or non-PBC(n = 145) at four cancer centers in China between 2003 and 2019 were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.33175DOI Listing

Low-dose cyclophosphamide and granulocyte colony-stimulating factor are sufficient for peripheral blood stem cell mobilization in patients with multiple myeloma.

Transfus Apher Sci 2020 Jun 6:102844. Epub 2020 Jun 6.

Department of Hematology, Erciyes University, Kayseri, Turkey.

Autologous stem cell transplantation (ASCT), supported by high-dose chemotherapy, is the prevalent option for multiple myeloma (MM) treatment in candidates suitable for transplantation. Although granulocyte colony-stimulating factor (G-CSF) supported cyclophosphamide (CY) is used as the pre-ASCT mobilization regimen, there is no consensus on the optimal dosage of CY. Thus, in this study, we examined the results of 47 MM patients, who underwent ASCT after mobilization with intermediate (ID) or low-dose (LD) CY treatment supported with G-CSF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transci.2020.102844DOI Listing

SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death.

Eur J Cancer 2020 Jun 6. Epub 2020 Jun 6.

Medical Oncology Division, Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto de Investigación 12 de Octubre, Madrid, Spain. Electronic address:

Aim: Previous studies have suggested a more frequent and severe course of novel coronavirus SARS-CoV-2 infection in cancer patients undergoing active oncologic treatment. Our aim was to describe the characteristics of the disease in this population and to determine predictive factors for poor outcome in terms of severe respiratory distress (acute respiratory distress syndrome [ARDS]) or death.

Patients And Methods: Patients consecutively admitted for SARS-CoV-2 infection were prospectively collected, and retrospective statistical analysis was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2020.06.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275164PMC

Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy.

Cancer 2020 Jun 25. Epub 2020 Jun 25.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Background: A high percentage of small cell lung cancer (SCLC) cases harbor cell cycle-related gene mutations and RICTOR amplification. Based on underlying somatic mutations, the authors have conducted a phase 2 biomarker-driven, multiarm umbrella study.

Methods: The SCLC Umbrella Korea StudiES (SUKSES) is an adaptive platform trial that undergoes continual modification according to the observed outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.33048DOI Listing

Phase 1/2 Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Relapsed/Refractory Primary Central Nervous System Lymphoma.

Neuro Oncol 2020 Jun 25. Epub 2020 Jun 25.

Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medic al Center, Saitama, Japan.

Background: The safety, tolerability, efficacy, and pharmacokinetics of tirabrutinib, a second-generation, highly selective oral Bruton's tyrosine kinase inhibitor were evaluated for relapsed/refractory primary central nervous system lymphoma (PCNSL).

Methods: Patients with relapsed/refractory PCNSL, Karnofsky performance status ≥70, and normal end-organ function received tirabrutinib 320 and 480 mg once daily (QD) in phase 1 to evaluate dose-limiting toxicity (DLT) within 28 days using a 3+3 dose escalation design and with 480 mg QD under fasted conditions in phase 2.

Results: Forty-four patients were enrolled; 20, seven and 17 received tirabrutinib at 320, 480 and 480 mg under fasted conditions, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noaa145DOI Listing

Clinical Features and Outcome of SARS-CoV-2 Infection in Children: A Systematic Review and Meta-analysis.

Indian Pediatr 2020 Jun 24. Epub 2020 Jun 24.

Post Graduate Institute of Medical Education and Research, Chandigarh, India. Correspondence to: Dr Jogender Kumar, Assistant Professor, Department of Pediatrics, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Background And Objective: Knowledge about COVID-19 in children is limited due to the paucity of reported data. The pediatric age group comprises only less than 5% of total COVID-19 worldwide, therefore, large studies in this population are unlikely in the immediate future. Hence, we planned to synthesize the current data that will help in a better understanding of COVID-19 in children. Read More

View Article

Download full-text PDF

Source
June 2020
1.014 Impact Factor

Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105).

Br J Haematol 2020 Jun 24. Epub 2020 Jun 24.

Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

We conducted a randomised phase II study to determine the optimal dose and schedule of melphalan, prednisone, and bortezomib (MPB) (jRCTs031180097). Transplant-ineligible untreated multiple myeloma patients were randomised to Arm A (twice weekly bortezomib in one six-week cycle followed by eight five-week cycles of four times once weekly bortezomib with melphalan and prednisolone on days 1-4) or Arm B (nine four-week cycles of three times once weekly bortezomib with melphalan and prednisolone on days 1-4). The primary end-point was complete response (CR) rate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16878DOI Listing

Effect of serum uric acid level and Multinational Association for Supportive Care in Cancer risk score on febrile neutropenia mortality.

Support Care Cancer 2020 Jun 25. Epub 2020 Jun 25.

Department of Medical Oncology, Gazi University, Ankara, Turkey.

Purpose: The study was aimed to evaluate the effect of uric acid (UA) on the 30-day mortality of patients admitted to the tertiary referral hospital with a complaint of febrile neutropenia (FEN). The secondary aim was to evaluate the use of combining serum UA levels with the Multinational Association for Supportive Care in Cancer (MASCC) risk score.

Methods: A retrospective study in which the MASCC score and serum UA levels were used to evaluate the mortality risk within 30 days among patients with FEN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-020-05587-7DOI Listing

Early Detection and Assessment of Covid-19.

Front Med (Lausanne) 2020 9;7:311. Epub 2020 Jun 9.

University College of Conventional Medicine, Faculty of Pharmacy & Alternative Medicine, The Islamia University of Bahawalpur, Bahawalpur, Pakistan.

Since the Covid-19 global pandemic emerged, developing countries have been facing multiple challenges over its diagnosis. We aimed to establish a relationship between the signs and symptoms of COVID-19 for early detection and assessment to reduce the transmission rate of SARS-Cov-2. We collected published data on the clinical features of Covid-19 retrospectively and categorized them into physical and blood biomarkers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmed.2020.00311DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296153PMC